Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults.^1,²Each year, approximately 20,000 Americans are diagnosed with CLL, with new cases at a rate of 4.9 per 100,000 in adult men and women.³ The estimated five-year survival for diagnosed patients is about 87 percent.³ Many newly diagnosed patients are put in “watch and wait,” where they are actively monitored for disease progression.⁴

Patients with CLL present with varying degrees of severity and mortality risks. Fortunately, clinical assays exist to test diagnosed patients for specific biomarkers — genetic mutations — that serve as predictors of disease progression and mortality.⁵Results from this simple test, known as cytogenetic/fluorescence in situ hybridization or “FISH,” may help guide treatment by providing key insights on the type of treatment needed.⁶

Read more at STAT...